Lista de obras - Marco Ladetto - Dominio Público Uruguay

13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

artículo científico

A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines

scientific article published on 28 February 2019

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

artículo científico publicado en 2018

A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease

artículo científico publicado en 2016

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

artículo científico publicado en 1997

A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.

artículo científico publicado en 2001

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

artículo científico

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

artículo científico publicado en 2015

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

artículo científico publicado en 2014

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.

artículo científico publicado en 2015

BRAF gene is not mutated in plasma cell leukemia and multiple myeloma

scientific article published on 01 November 2003

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia

artículo científico publicado en 2008

Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.

artículo científico publicado en 2006

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

scientific article published on 01 August 1996

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma ⬇️

artículo científico publicado el 1 de junio de 2013

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

artículo científico publicado en 2015

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status

artículo científico publicado en 2009

Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network

artículo científico publicado en 2015

Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain

artículo científico publicado en 2013

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

artículo científico publicado en 2001

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

artículo científico publicado en 2005

Data quality improvement of a multicenter clinical trial dataset

artículo científico publicado en 2017

Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype

artículo científico publicado en 2011

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2015

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

artículo científico publicado en 2012

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

artículo científico publicado en 2013

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

artículo científico publicado en 2018

Epigenomic evolution in diffuse large B-cell lymphomas

artículo científico publicado en 2015

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

scientific article published on 04 July 2016

Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis

artículo científico publicado en 2017

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2013

Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.

artículo científico publicado en 2011

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data

artículo científico publicado en 2017

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

scientific article published on February 2014

High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission

artículo científico publicado en 2006

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells

artículo científico publicado en 2011

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

article

Infections and Follicular Lymphoma: is there a Link?

artículo científico publicado en 2017

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

artículo científico publicado en 2014

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

artículo científico publicado en 2012

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

artículo científico publicado en 2017

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

artículo científico publicado en 2014

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

artículo científico publicado en 2013

Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes

article

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

artículo científico publicado en 2000

Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir

scientific article published on 01 April 2007

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

artículo científico publicado en 2014

Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome

artículo científico publicado en 2010

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

artículo científico publicado en 2014

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

artículo científico publicado en 2012

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

artículo científico publicado en 2007

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

artículo científico publicado en 2005

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

artículo científico publicado en 2008

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

artículo científico publicado en 2015

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial

artículo científico publicado en 2014

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

artículo científico publicado en 2011

N- and K-ras oncogenes in plasma cell dyscrasias.

artículo científico publicado en 1994

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions

scientific article published on 01 September 1999

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2017

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

scientific article published on 01 September 2016

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2017

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

artículo científico publicado en 2013

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

artículo científico publicado en 2018

PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.

artículo científico publicado en 2003

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.

artículo científico publicado en 2003

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2015

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

artículo científico publicado en 2013

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

artículo científico publicado en 2017

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial

scientific article published on 24 August 2006

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

artículo científico publicado en 2007

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

artículo científico publicado en 2015

Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system

scientific article published on 01 June 2002

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

artículo científico publicado en 2016

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

artículo científico publicado en 2000

Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests

scientific article published on 01 June 2002

Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.

artículo científico publicado en 2003

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

artículo científico publicado en 2006

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

artículo científico publicado en 2013

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

artículo científico publicado en 2016

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

artículo científico publicado en 2017

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells.

artículo científico publicado en 2015

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

artículo científico publicado en 2018

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

artículo científico publicado en 2016

Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

artículo científico publicado en 2009

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.

artículo científico publicado en 2011

Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders

artículo científico publicado en 2004

Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients

scientific article published on 15 February 2007

Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia.

artículo científico publicado en 2009

Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.

artículo científico publicado en 2012

Telomeres and telomerase in normal and malignant B-cells.

artículo científico publicado en 2010

The adulthood of MRD detection in MCL

artículo científico publicado en 2010

The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma

artículo científico publicado en 2010

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

artículo científico publicado en 2013

The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma

artículo científico publicado en 1993

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

artículo científico publicado en 2007

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

artículo científico publicado en 2016

Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

artículo científico publicado en 2013

Lista de obras de Marco Ladetto

13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia

A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.

A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients.

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi.

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.

BRAF gene is not mutated in plasma cell leukemia and multiple myeloma

CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia

Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.

Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma

Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma ⬇️

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status

Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network

Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

Data quality improvement of a multicenter clinical trial dataset

Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.

ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.

ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

Epigenomic evolution in diffuse large B-cell lymphomas

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis

Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia.

HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission

IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

Infections and Follicular Lymphoma: is there a Link?

Inter- and intratumoral heterogeneity of BCL2 correlates with IgH expression and prognosis in follicular lymphoma.

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas

Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi

Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

Low CD49d expression and long telomere identify a chronic lymphocytic leukemia subset with highly favourable outcome

MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes.

N- and K-ras oncogenes in plasma cell dyscrasias.

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma

PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy.

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up.

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests

Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone.

Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italia

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi